Log in to search using one of your social media accounts:

 

HRT for Menopause?

Thisarticle I saw on Yahoo News is an example of why patients ought not to go scouring the Internet for all their medical information.  The title of the article "Doctors Clear Up Confusion Over Hormone Therapy" is rather misleading.  Hormone replacement therapy (i.e. supplement estrogen and progesterone pills) has long been known to be the best intervention for refractory menopausal symptoms.  Unfortunately, a Women's Health Initiative study from a decade ago demonstrated that subsets of post-menopausal of women who took hormonal replacement therapy (HRT) medication increased their risk of developing breast cancer by 25%.  Afterwards, enthusiasm for HRT sort of tapered off.  As you could imagine.  This new statement avers that:...while the therapy comes with risks, its benefits generally outweigh the harm for women under age 60, or those who've been in menopause for fewer than 10 years. The increased risk ofbreast cancer also appears to disappear a few years after treatment is stopped......doctors recommend low doses of HRT for women whosemenopausal symptoms are limited to vaginal dryness and pain during intercourse. HRT is not recommended for women who've had breast cancer So if you're under 60, have had symptoms less than 10 years, never had breast cancer, and your symptoms are limited to vaginal dryness and dyspareunia, then HRT is for you.  I'm a little wary myself.  Curiously absent from the ...
Source: Buckeye Surgeon - Category: Surgery Authors: Source Type: blogs

Related Links:

ConclusionsWhile QoL in disease-free breast cancer survivors 5  years post-diagnosis was largely comparable to the general population on average, still many survivors suffered from adverse effects. There appears to be a need for ongoing screening and support regarding fatigue, sleep problems, cognitive problems, arthralgia/pain, menopausal/sexual symptoms, phy sical performance, and weight problems during and several years following breast cancer therapy.
Source: Quality of Life Research - Category: Health Management Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
CONCLUSIONS: While some menopausal-related symptom clusters were consistent across time and dimensions, the majority of symptoms clustered together differently depending on whether they were evaluated prior to or at 12 months after breast cancer surgery. An increased understanding of how symptom clusters change over time may assist clinicians to focus their symptom assessments and management strategies. PMID: 29353634 [PubMed - in process]
Source: European Journal of Oncology Nursing - Category: Nursing Authors: Tags: Eur J Oncol Nurs Source Type: research
Approximately 60% to 100% of women with breast cancer experience at least one menopausal-related symptom. Little is known about associations between menopausal status and symptoms in women 12 months after breast cancer surgery.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Tags: Original Article Source Type: research
Abstract BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breast canc...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
This study, the first to examine potential adverse health effects in users of vaginal estrogen compared with non-users, suggests that vaginal estrogen therapy is a safe treatment for genitourinary symptoms such as burning, discomfort, and pain during intercourse associated with menopause.AUTHORSThe paper ’s authors are Dr. Carolyn Crandall of UCLA; Kathleen Hovey of the State University of New York at Buffalo; Christopher Andrews of the University of Michigan; Dr. Rowan Chlebowski of City of Hope; Marcia Stefanick of Stanford University; Dr. Dorothy Lane of the State University of New York at Ston y Brook; Dr. Jan Sh...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
ConclusionsThis review established a set of evidence-based predictors that can be used to help identify women at higher risk of experiencing distress following completion of primary breast cancer treatment.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Doctors have been adding a new tool to the arsenal of how they restore the sex lives of menopausal and post-menopausal women: the humble vibrator. With the onset of menopause, a decrease in the production of hormones causes vaginal tissue to get thinner and drier. Vaginal muscles can also atrophy, leading to painful sex ― a problem for half of all menopausal and post-menopausal women, according to the National Institutes of Health. But the solution might be as simple as a vibrating piece of silicon.  Vibrators that are used internally stimulate pelvic blood flow, which increases vaginal mois...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
TRENTON, N.J. (AP) — Johnson &Johnson has been hit with a multimillion-dollar jury verdict for the fourth time over whether the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene. Late Thursday, a St. Louis jury awarded $110.5 million to Lois Slemp, 62, of Wise, Virginia, who was diagnosed with ovarian cancer in 2012. She blames her illness on her use of the company’s talcum powder-containing products for more than 40 years. Besides Slemp’s case, three other jury trials in St. Louis reached similar outcomes last year, awarding the plaintiffs $72 million, $...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News baby powder Cancer Source Type: news
This study elucidated adherence as a complex continuum of behaviors, appraisals, and decision points. These insights may be particularly useful in counseling survivors taking AET and promoting timely delivery of clinical interventions to enhance adherence.
. IMPLICATIONS FOR NURSING: Nurses should be involved in the planning and implementation of clinical interventions to manage side effects and other barriers to AET adherence. PMID: 28635973 [PubMed - in process]
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
More News: American Medical Association (AMA) | Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Internet | Men | Menopause | Pain | Study | Surgeons | Women